|
1
|
Pichler M, Hutterer GC, Chromecki TF,
Jesche J, Kampel-Kettner K, Pummer K and Zigeuner R: Renal cell
carcinoma stage migration in a single European centre over 25
years: Effects on 5- and 10-year metastasis-free survival. Int Urol
Nephrol. 44:997–1004. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Athar U and Gentile TC: Treatment options
for metastatic renal cell carcinoma: A review. Can J Urol.
15:3954–3966. 2008.PubMed/NCBI
|
|
5
|
Ljungberg B, Bensalah K, Canfield S,
Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L,
Merseburger AS, et al: EAU guidelines on renal cell carcinoma: 2014
update. Eur Urol. 67:913–924. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Oh-I S, Shimizu H, Satoh T, Okada S,
Adachi S, Inoue K, Eguchi H, Yamamoto M, Imaki T, Hashimoto K, et
al: Identification of nesfatin-1 as a satiety molecule in the
hypothalamus. Nature. 443:709–712. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Massari F, Ciccarese C, Santoni M,
Brunelli M, Piva F, Modena A, Bimbatti D, Fantinel E, Santini D,
Cheng L, et al: Metabolic alterations in renal cell carcinoma.
Cancer Treat Rev. 41:767–776. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang P, Sun Y and Ma L: ZEB1: At the
crossroads of epithelial mesenchymal transition, metastasis and
therapy resistance. Cell Cycle. 14:481–487. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu W, Huang YJ, Liu C, Yang YY, Liu H,
Cui JG, Cheng Y, Gao F, Cai JM and Li BL: Inhibition of TBK1
attenuates radiation-induced epithelial-mesenchymal transition of
A549 human lung cancer cells via activation of GSK-3β and
repression of ZEB1. Lab Invest. 94:362–370. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu Z, Sun B, Qi L, Li H, Gao J and Leng
X: Zinc finger E-box binding homeobox 1 promotes vasculogenic
mimicry in colorectal cancer through induction of
epithelial-to-mesenchymal transition. Cancer Sci. 103:813–820.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li H, Song S, Xu Y, Zhao J and Liu H:
Knockdown of ZEB1 suppresses the formation of vasculogenic mimicry
in breast cancer cell line MDA-MB- 231 through downregulation of
Flk-1. Minerva Med. 108:191–193. 2017.PubMed/NCBI
|
|
13
|
Pavlides S, Tsirigos A, Migneco G,
Whitaker-Menezes D, Chiavarina B, Flomenberg N, Frank PG, Casimiro
MC, Wang C, Pestell RG, et al: The autophagic tumor stroma model of
cancer: Role of oxidative stress and ketone production in fueling
tumor cell metabolism. Cell Cycle. 9:3485–3505. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Martinez-Outschoorn UE, Balliet RM,
Rivadeneira DB, Chiavarina B, Pavlides S, Wang C, Whitaker-Menezes
D, Daumer KM, Lin Z, Witkiewicz AK, et al: Oxidative stress in
cancer associated fibroblasts drives tumor-stroma co-evolution: A
new paradigm for understanding tumor metabolism, the field effect
and genomic instability in cancer cells. Cell Cycle. 9:3256–3276.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kang J, Shakya A and Tantin D: Stem cells,
stress, metabolism and cancer: A drama in two Octs. Trends Biochem
Sci. 34:491–499. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li QC, Wang HY, Chen X, Guan HZ and Jiang
ZY: Fasting plasma levels of nesfatin-1 in patients with type 1 and
type 2 diabetes mellitus and the nutrient-related fluctuation of
nesfatin-1 level in normal humans. RegulPept. 159:72–77. 2010.
|
|
17
|
Gonzalez R, Reingold BK, Gao X, Gaidhu MP,
Tsushima RG and Unniappan S: Nesfatin-1 exerts a direct,
glucose-dependent insulinotropic action on mouse islet β-and MIN6
cells. J Endocrinol. 208:R9–R16. 2011.PubMed/NCBI
|
|
18
|
Suzuki S, Takagi K, Miki Y, Onodera Y,
Akahira J, Ebata A, Ishida T, Watanabe M, Sasano H and Suzuki T:
Nucleobindin 2 in human breast carcinoma as a potent prognostic
factor. Cancer Sci. 103:136–143. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cao X, Liu XM and Zhou LH: Recent progress
in research on the distribution and function of NUCB-2/nesfatin-1
in peripheral tissues. Endocr J. 60:1021–1027. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang H, Qi C, Wang A, Yao B, Li L, Wang Y
and Xu Y: Prognostication of prostate cancer based on NUCB-2
protein assessment: NUCB-2 in prostate cancer. J Exp Clin Cancer
Res. 32:772013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang H, Qi C, Li L, Luo F and Xu Y:
Clinical significance of NUCB-2 mRNA expression in prostate cancer.
J Exp Clin Cancer Res. 32:562013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang H, Qi C, Wang A, Li L and Xu Y: High
expression of nucleobindin 2 mRNA: An independent prognostic factor
for overall survival of patients with prostate cancer. Tumour Biol.
35:2025–2028. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Qi C, Ma H, Zhang HT, Gao JD and Xu Y:
Nucleobindin 2 expression is an independent prognostic factor for
clear cell renal cell carcinoma. Histopathology. 66:650–657. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Stengel A, Goebel M, Yakubov I, Wang L,
Witcher D, Coskun T, Taché Y, Sachs G and Lambrecht NW:
Identification and characterization of nesfatin-1 immunoreactivity
in endocrine cell types of the rat gastric oxyntic mucosa.
Endocrinology. 150:232–238. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
William WN, Kim JS, Liu DD, Solis L,
Behrens C, Lee JJ, Lippman SM, Kim ES, Hong WK and Lee HY: The
impact of phosphorylated AMP-activated protein kinase expression on
lung cancer survival. Ann Oncol. 23:78–85. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zong H, Yin B, Zhou H, Cai D, Ma B and
Xiang Y: Inhibition of mTOR pathway attenuates migration and
invasion of gallbladder cancer via EMT inhibition. Mol Biol Rep.
41:4507–4512. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lam JS, Klatte T and Breda A: Staging of
renal cell carcinoma: Current concepts. Indian J Urol. 25:446–454.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ebert T, Bander NH, Finstad CL, Ramsawak
RD and Old LJ: Establishment and characterization of human renal
cancer and normal kidney cell lines. Cancer Res. 50:5531–5536.
1990.PubMed/NCBI
|
|
29
|
Gregersen I, Skjelland M, Holm S, Holven
KB, Krogh-Sørensen K, Russell D, Askevold ET, Dahl CP, Ørn S,
Gullestad L, et al: Increased systemic and local interleukin 9
levels in patients with carotid and coronary atherosclerosis. PLoS
One. 8:e727692013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Brodaczewska KK, Szczylik C, Fiedorowicz
M, Porta C and Czarnecka AM: Choosing the right cell line for renal
cell cancer research. Mol Cancer. 15:832016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Takeyama Y, Sato M, Horio M, Hase T,
Yoshida K, Yokoyama T, Nakashima H, Hashimoto N, Sekido Y, Gazdar
AF, et al: Knockdown of ZEB1, a master epithelial-to-mesenchymal
transition (EMT) gene, suppresses anchorage-independent cell growth
of lung cancer cells. Cancer Lett. 296:216–224. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu Y, El-Naggar S, Darling DS, Higashi Y
and Dean DC: Zeb1 links epithelial-mesenchymal transition and
cellular senescence. Development. 135:579–588. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sánchez-Tilló E, Liu Y, de Barrios O,
Siles L, Fanlo L, Cuatrecasas M, Darling DS, Dean DC, Castells A
and Postigo A: EMT-activating transcription factors in cancer:
Beyond EMT and tumor invasiveness. Cell Mol Life Sci. 69:3429–3456.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xu Y, Pang XY, Dong M, Wen F and Zhang Y:
Nesfatin-1 inhibits ovarian epithelial carcinoma cell proliferation
in vitro. Biochem Biophys Res Commun. 440:467–472. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang ML, Zhang ZH, Wang C, Li K, Li SB,
Boden G, Li L and Yang GY: Nesfatin-1 action in the brain increases
insulin sensitivity through Akt/AMPK/TORC2 pathway in diet-induced
insulin resistance. Diabetes. 61:1959–1968. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li Z, Xu G, Li Y, Zhao J, Mulholland MW
and Zhang W: mTOR-dependent modulation of gastric
nesfatin-1/NUCB-2. Cell PhysiolBiochem. 29:493–500. 2012.
|
|
38
|
Saxton RA and Sabatini DM: mTOR signaling
in growth, metabolism, and disease. Cell. 9:960–976. 2017.
View Article : Google Scholar
|
|
39
|
Wullschleger S and Loewith R: TOR
signaling in growth and metabolism. Cell. 124:471–484. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Laplante M and Sabatini DM: mTOR signaling
in growth control and disease. Cell. 149:274–293. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Huang K and Fingar DC: Growing knowledge
of the mTOR signalling network. Semin Cell Dev Biol. 36:79–90.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ma XM and Blenis J: Molecular mechanisms
of mTOR-mediated translational control. Nat Rev Mol Cell Biol.
10:307–318. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Viollet B, Horman S, Leclerc J, Lantier L,
Foretz M, Billaud M, Giri S and Andreelli F: AMPK inhibition in
health and disease. Crit Rev Biochem Mol Biol. 45:276–295. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Fu H, Zhu Y, Wang Y, Liu Z, Zhang J, Wang
Z, Xie H, Dai B, Xu J and Ye D: High NUCB2 expression level
represents an independent negative prognostic factor in Chinese
cohorts of non-metastatic clear cell renal cell carcinoma patients.
Oncotarget. 15:9188–9194. 2016.
|
|
45
|
Pinheiro C, Garcia EA, Morais-Santos F,
Moreira MA, Almeida FM, Jubé LF, Queiroz GS, Paula ÉC, Andreoli MA,
Villa LL, et al: Reprogramming energy metabolism and inducing
angiogenesis: Co-expression of monocarboxylate transporters with
VEGF family members in cervical adenocarcinomas. BMC Cancer.
15:8352015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Saeidi N, Meoli L, Nestoridi E, Gupta NK,
Kvas S, Kucharczyk J, Bonab AA, Fischman AJ, Yarmush ML and
Stylopoulos N: Reprogramming of intestinal glucose metabolism and
glycemic control in rats after gastric bypass. Science.
341:406–410. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Soga T: Cancer metabolism: Key players in
metabolic reprogramming. Cancer Sci. 104:275–281. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Rattan R, Giri S, Singh AK and Singh I:
5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits
cancer cell proliferation in vitro and in vivo via AMP-activated
protein kinase. J Biol Chem. 280:39582–39593. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Dong D, Cai GY, Ning YC, Wang JC, Lv Y,
Hong Q, Cui SY, Fu B, Guo YN and Chen XM: Alleviation of senescence
and epithelial-mesenchymal transition in aging kidney by short-term
caloric restriction and caloric restriction mimetics via modulation
of AMPK/mTOR signaling. Oncotarget. 8:16109–16121. 2017.PubMed/NCBI
|
|
50
|
Liu T, Sun Q, Li Q, Yang H, Zhang Y, Wang
R, Lin X, Xiao D, Yuan Y, Chen L and Wang W: Dual PI3K/mTOR
inhibitors, GSK2126458 and PKI-587, suppress tumor progression and
increase radiosensitivity in nasopharyngeal carcinoma. Mol Cancer
Ther. 14:429–439. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kan JY, Yen MC, Wang JY, Wu DC, Chiu YJ,
Ho YW and Kuo PL: Nesfatin-1/Nucleobindin-2 enhances cell
migration, invasion, and EMT via LKB1/AMPK/TORC1/ZEB1 pathways in
colon cancer. Oncotarget. 7:31336–31349. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Sun S, Hang T, Zhang B, Zhu L, Wu Y, Lv X,
Huang Q and Yao H: miRNA-708 functions as a tumor suppressor in
colorectal cancer by targeting ZEB1 through Akt/mTOR signaling
pathway. Am J Transl Res. 11:5338–5356. 2019.PubMed/NCBI
|
